NCT04547907
A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer treatment 3 recruiting NCT00496366
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer treatment 2 terminated NCT02080390
Strain Imaging in Breast Cancer Patients Receiving Trastuzumab No drug interventions Not Available Not Available completed NCT06100874
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) treatment 2 recruiting NCT02488564
A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer treatment 2 completed NCT01361945
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer treatment 1 / 2 withdrawn NCT01565200
HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 diagnostic 2 active_not_recruiting NCT02568839
Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer treatment 2 / 3 active_not_recruiting NCT01583426
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) treatment 3 completed NCT02675231
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer treatment 2 completed NCT00788931
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer treatment 1 completed NCT02154529
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer treatment 1 / 2 terminated NCT02598310
Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer treatment 2 terminated NCT01677455
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer treatment 2 completed NCT01432223
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab treatment 2 completed NCT02102438
Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer treatment Not Available withdrawn NCT01388647
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer treatment 1 / 2 terminated NCT02492711
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer treatment 3 completed NCT02947685
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer treatment 3 active_not_recruiting NCT02066532
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer treatment 1 / 2 completed NCT02131506
A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer treatment 1 terminated NCT04644406
PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study No drug interventions Not Available Not Available unknown_status NCT05871918
A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer No drug interventions treatment 3 recruiting NCT01305941
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases treatment 2 completed NCT01340430
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer treatment 2 completed NCT01433926
Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years No drug interventions Not Available Not Available completed NCT02326974
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA treatment 2 active_not_recruiting NCT01426880
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer treatment 2 / 3 completed NCT01428414
Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer treatment 2 unknown_status NCT06603597
HER2-positive Breast Cancer Registry No drug interventions Not Available Not Available recruiting NCT01598077
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer treatment 1 completed NCT03975647
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer treatment 3 active_not_recruiting NCT04419181
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer treatment 2 suspended NCT04278144
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors treatment 1 / 2 active_not_recruiting NCT04360941
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer other 1 recruiting NCT05954143
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer treatment 2 active_not_recruiting NCT06123988
Prolonged Overnight Fasting And/or Exercise on Fatigue and Other Patient Reported Outcomes in Women with Hormone Receptor Positive Advanced Breast Cancer No drug interventions supportive_care Not Available recruiting NCT05132582
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer treatment 3 active_not_recruiting NCT04425018
MARGetuximab Or Trastuzumab (MARGOT) treatment 2 active_not_recruiting NCT04569747
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer treatment 2 recruiting NCT04893109
ATEMPT 2.0: Adjuvant T-DM1 Vs TH treatment 2 recruiting NCT05868226
PRE-I-SPY Phase I/Ib Oncology Platform Program treatment 1 recruiting NCT05721248
STOP-HER2: Stopping Trastuzumab in HER2+ MBC No drug interventions treatment 2 recruiting NCT05705401
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer No drug interventions treatment 3 recruiting NCT06210776
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) Not Available Not Available recruiting NCT06386263
HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada Not Available Not Available recruiting NCT06328738
ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer treatment 1 recruiting NCT04675827
De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade treatment 2 suspended NCT04588545
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease treatment 1 / 2 recruiting NCT04886531
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers treatment 2 recruiting NCT05036252
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity No drug interventions Not Available Not Available recruiting NCT05149014
Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer No drug interventions Not Available Not Available completed NCT05115474
Study of Screening Brain MRIs in Stage IV Breast Cancer No drug interventions Not Available Not Available recruiting NCT06016387
Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD treatment 2 recruiting NCT06172127
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer treatment 2 recruiting NCT06220214
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer diagnostic 0 recruiting NCT05474690
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer treatment 3 withdrawn NCT04756921
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response Not Available Not Available completed NCT04095390
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer treatment 2 unknown_status NCT03602079
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene No drug interventions treatment 1 / 2 completed NCT05234021
HER2-directed Biosimilar in Breast Cancer: Real World ePRO No drug interventions Not Available Not Available completed NCT03112590
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer treatment 1 / 2 completed NCT01722890
CharactHer. ICORG 12-09, V3 No drug interventions Not Available Not Available terminated NCT01042379
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer treatment 2 recruiting NCT01037790
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer treatment 2 completed NCT01904903
Cardiac Safety Study in Patients With HER2 + Breast Cancer treatment 2 completed NCT06548178
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer No drug interventions treatment 2 not_yet_recruiting NCT06414733
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors No drug interventions treatment 1 not_yet_recruiting NCT06068985
Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade treatment 2 not_yet_recruiting NCT05982678
Basket Study for Oligo-metastatic Breast Cancer treatment 2 recruiting NCT05388149
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease treatment 2 recruiting NCT05346224
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer treatment 3 active_not_recruiting NCT05367739
Real World Study on the Efficacy and Safety of Anti-HER2 Therapy No drug interventions Not Available Not Available completed NCT05306041
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer treatment 2 recruiting NCT05514717
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 treatment 1 recruiting NCT04997798
Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer treatment 2 recruiting NCT04789096
Tucatinib Together With Pembrolizumab and Trastuzumab treatment 2 recruiting NCT06439693
The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer treatment 2 not_yet_recruiting NCT04602117
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer treatment 1 withdrawn NCT04487236
Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors treatment 1 recruiting NCT04481932
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer treatment 2 recruiting NCT04457700
CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC No drug interventions Not Available Not Available unknown_status NCT04337658
Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer treatment 3 not_yet_recruiting NCT04281641
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer No drug interventions diagnostic Not Available recruiting NCT06313086
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer treatment 3 recruiting NCT04246671
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer No drug interventions treatment 1 active_not_recruiting NCT04142554
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer basic_science 1 withdrawn NCT04094896
TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer No drug interventions treatment 2 unknown_status NCT03981705
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer No drug interventions Not Available Not Available active_not_recruiting NCT03953833
B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer No drug interventions treatment 1 completed NCT03933319
Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer treatment 2 unknown_status NCT03913234
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients treatment 1 / 2 unknown_status NCT03847818
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer treatment Not Available unknown_status NCT03811418
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer other 3 withdrawn NCT03738553
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy Not Available Not Available active_not_recruiting NCT04030507
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer No drug interventions screening Not Available recruiting NCT03556358
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer treatment 3 completed NCT03521245
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer Not Available Not Available unknown_status NCT04638725
Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer No drug interventions Not Available Not Available recruiting NCT05582499
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy treatment 2 recruiting NCT05412459
99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy No drug interventions Not Available Not Available completed NCT05134519
RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer No drug interventions treatment 2 not_yet_recruiting NCT06348134
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery treatment 2 not_yet_recruiting NCT05599334
A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib No drug interventions Not Available Not Available recruiting NCT05698186
Thero2-01S22 in HER2-positive Breast Cancer No drug interventions treatment 3 not_yet_recruiting NCT05750693
PIK3CA in HER2+ BC and pCR Trial No drug interventions treatment Not Available active_not_recruiting NCT05692661
A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer No drug interventions treatment 1 recruiting NCT03387553
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer No drug interventions treatment 0 active_not_recruiting NCT03330561
PRS-343 in HER2-Positive Solid Tumors treatment 1 completed NCT03281824
Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients other 1 completed NCT03133988
Margetuximab Expanded Access Program Not Available Not Available approved_for_marketing NCT03094052
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib treatment 2 completed NCT05036005
Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) treatment 4 recruiting NCT05433753
Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study No drug interventions Not Available Not Available recruiting NCT02135159
Patients With Brain Metastases From HER2-positive Breast Cancer No drug interventions treatment 1 completed NCT02060253
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer treatment 1 completed NCT01912963
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer treatment 2 terminated NCT01730833
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer treatment 2 active_not_recruiting NCT01632332
Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer treatment 1 completed NCT01245205
Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer treatment 1 completed NCT00791037
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer treatment 1 / 2 completed NCT00436254
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer treatment 1 active_not_recruiting NCT00331552
Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer treatment 1 / 2 completed NCT00343109
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer prevention 2 completed NCT00098605
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases treatment 2 completed NCT05406635
Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer No drug interventions treatment Not Available recruiting NCT04276337
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy No drug interventions Not Available Not Available unknown_status NCT04042051
Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer treatment 1 terminated NCT02993198
A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging prevention 2 active_not_recruiting NCT02682693
Denosumab as an add-on Neoadjuvant Treatment (GeparX) treatment 2 completed NCT05252988
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib prevention 2 recruiting NCT02705859
Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) treatment 1 completed NCT02476539
Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer No drug interventions treatment 1 completed NCT06533670
TME Alteration in HER2 Positive Breast Cancer No drug interventions Not Available Not Available recruiting NCT06479460
Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients No drug interventions Not Available Not Available recruiting NCT06441890
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer treatment 2 recruiting NCT06445400
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer treatment 2 recruiting NCT06217185
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). treatment 4 recruiting NCT06107790
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer treatment 3 completed NCT05985187
Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer. treatment 3 active_not_recruiting NCT05955170
Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer treatment 2 recruiting NCT05955521
Exosome as the Prognostic and Predictive Biomarker in EBC Patients No drug interventions screening Not Available active_not_recruiting NCT05955833
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study No drug interventions diagnostic 1 recruiting NCT05809752
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) No drug interventions treatment 1 recruiting NCT05769751
A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer No drug interventions Not Available Not Available completed NCT05760612
A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment With Trastuzumab Combined With Parezumab treatment 3 recruiting NCT05720026
Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer treatment 3 recruiting NCT05710666
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) treatment 2 active_not_recruiting NCT05635487
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients treatment 2 recruiting NCT05388500
Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C) treatment 3 not_yet_recruiting NCT05378464
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer treatment 1 recruiting NCT05346861
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab treatment 3 recruiting NCT05346107
PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer treatment 2 unknown_status NCT05169853
Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer No drug interventions Not Available Not Available active_not_recruiting NCT05063643
Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude No drug interventions Not Available Not Available not_yet_recruiting NCT04660929
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors treatment 1 active_not_recruiting NCT04650451
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors No drug interventions treatment 1 suspended NCT06265428
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer treatment 3 recruiting NCT04605575
Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer treatment 2 unknown_status NCT04609540
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC Not Available Not Available unknown_status NCT04512261
TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases treatment 1 / 2 withdrawn NCT04464967
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers treatment 1 / 2 withdrawn NCT04450732
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT04332588
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI No drug interventions diagnostic 1 recruiting NCT04158856
Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer treatment 2 not_yet_recruiting NCT06330012
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients. No drug interventions screening Not Available recruiting NCT04395508
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic Not Available Not Available approved_for_marketing NCT04220203
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer Not Available Not Available approved_for_marketing NCT04158505
Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer No drug interventions Not Available Not Available unknown_status NCT04109391
Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 treatment 3 completed NCT04088110
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer treatment 2 unknown_status NCT04011085
Tw HER2 Positive Breast Cancer Productivity & Utility Study No drug interventions Not Available Not Available unknown_status NCT03919253
Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study treatment 2 unknown_status NCT03907800
Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer treatment 2 recruiting NCT03910712
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC treatment 2 unknown_status NCT03881605
MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients With Triple Negative or HER2+ MBC No drug interventions screening Not Available unknown_status NCT03894007
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer treatment 2 terminated NCT03879577
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer treatment 2 recruiting NCT03881878
TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery No drug interventions treatment 1 / 2 unknown_status NCT03812393
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast treatment 2 active_not_recruiting NCT03709082
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer treatment 1 / 2 terminated NCT03698383
Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer treatment 2 unknown_status NCT04033172
Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant ) treatment 2 unknown_status NCT03655353
A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer No drug interventions diagnostic Not Available recruiting NCT03630809
Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 No drug interventions treatment 2 terminated NCT03588091
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer treatment 3 unknown_status NCT03571633
Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer treatment 2 recruiting NCT04158947
A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone treatment 2 unknown_status NCT04639271
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis treatment 2 unknown_status NCT05020860
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer treatment 2 recruiting NCT05091528
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers treatment 1 / 2 terminated NCT05458401
EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan Not Available Not Available completed NCT05189067
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer treatment 2 / 3 recruiting NCT05227131
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer treatment 2 withdrawn NCT05334810
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer treatment 2 unknown_status NCT05325632
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab treatment 2 recruiting NCT05555251
BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT05834764
Pyrotinib in Women With High-risk in Early Stage Breast Cancer treatment 2 recruiting NCT05912062
Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer Not Available Not Available recruiting NCT05918328
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC treatment 2 recruiting NCT04420598
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease treatment 2 completed NCT03125928
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer treatment 2 active_not_recruiting NCT03140553
TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer treatment 2 completed NCT03460067
Omission of Radiation in Patients With Her-2 Positive Breast Cancer No drug interventions treatment Not Available terminated NCT03384914
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer No drug interventions treatment 2 active_not_recruiting NCT03319459
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors treatment 1 completed NCT03238495
Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer treatment 2 unknown_status NCT03085368
A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin treatment 2 / 3 unknown_status NCT05429294
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038 treatment 2 recruiting NCT04578106
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy treatment 2 recruiting NCT04034823
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer treatment 2 unknown_status NCT02379585
Fasting on Newly Diagnosed Breast Cancer treatment 1 / 2 terminated NCT02226276
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer diagnostic Not Available active_not_recruiting NCT02038010
BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx treatment 1 completed NCT01873833
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer treatment 2 terminated NCT01855828
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer treatment 2 completed NCT01783756
Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis treatment 1 / 2 completed NCT01729884
Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer treatment 2 terminated NCT01712815
PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer No drug interventions diagnostic Not Available terminated NCT01688609
Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer treatment 2 completed NCT01355393
Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer treatment 1 / 2 completed NCT01217411
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer treatment 1 terminated NCT01219907
Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer treatment 1 withdrawn NCT00407888
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery treatment 2 completed NCT00194779
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery treatment 2 completed NCT00079326
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer treatment 2 terminated NCT00006228
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer treatment 2 completed NCT00003440
Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic treatment 3 completed NCT01785420
Pre Operative Trastuzumab in Operable Breast Cancer treatment 3 recruiting NCT02125344
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) treatment 3 completed NCT03013504
A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients treatment 3 completed NCT04539938
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer treatment 2 active_not_recruiting NCT03947242
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer. treatment Not Available unknown_status NCT01840306
Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer No drug interventions Not Available Not Available completed NCT06518382
Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients No drug interventions Not Available Not Available not_yet_recruiting NCT06446882
Diagnostic HER2DX-guided Treatment for patIents wIth Early-stage HER2-positive Breast Cancer No drug interventions other Not Available not_yet_recruiting NCT06358625
Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer No drug interventions Not Available Not Available recruiting NCT06087120
Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer. No drug interventions Not Available Not Available recruiting NCT06035016
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer Not Available Not Available recruiting NCT05982626
Study of 68Ga /131I SGMIB-ZT-199 PET Imaging Targeting HER2-positive in the Diagnosis of Metastatic Breast Cancer No drug interventions diagnostic Not Available recruiting NCT05945368
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC treatment 2 recruiting NCT05795101
TRUDI: TDXD+Durva in HER2+/low IBC treatment 2 recruiting NCT05511844
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT05371860
Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response No drug interventions treatment 2 withdrawn NCT05154396
Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer treatment 2 not_yet_recruiting NCT05076695
Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer treatment 2 recruiting NCT05019365
Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy No drug interventions Not Available Not Available unknown_status NCT04899908
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases treatment 2 recruiting NCT04802876
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors treatment 2 recruiting NCT04760431
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) treatment 2 not_yet_recruiting NCT06276868
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer treatment 2 not_yet_recruiting NCT06161922
Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy No drug interventions Not Available Not Available recruiting NCT04288141
A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies No drug interventions Not Available Not Available recruiting NCT06328465
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases No drug interventions diagnostic Not Available recruiting NCT06316531
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer treatment 3 recruiting NCT04993014
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer treatment 2 recruiting NCT04236310
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. treatment 2 unknown_status NCT04225858
Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy No drug interventions treatment Not Available not_yet_recruiting NCT04170595
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection treatment 1 / 2 unknown_status NCT04106167
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy No drug interventions Not Available Not Available terminated NCT03841110
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors treatment 1 completed NCT03747120
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab treatment 2 active_not_recruiting NCT03696030
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases No drug interventions treatment 1 recruiting NCT03684863
Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy treatment 2 not_yet_recruiting NCT03650348
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors treatment 1 completed NCT03644186
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) treatment 2 completed NCT03619044
The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane. No drug interventions other Not Available terminated NCT03530696
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer treatment 2 completed NCT03500380
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases treatment 2 / 3 active_not_recruiting NCT04957212
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer treatment 3 completed NCT05561686
Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer Not Available Not Available not_yet_recruiting NCT05553522
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer treatment 1 recruiting NCT05593094
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors treatment 1 recruiting NCT05904730
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations treatment 1 enrolling_by_invitation NCT06281210
Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery No drug interventions treatment Not Available recruiting NCT05880160
Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction No drug interventions treatment Not Available recruiting NCT03179904
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer treatment 2 active_not_recruiting NCT05426486
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients treatment 2 / 3 active_not_recruiting NCT04582968
Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases No drug interventions treatment 1 / 2 active_not_recruiting NCT02345772
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy treatment 1 / 2 terminated NCT02095210
HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025 No drug interventions diagnostic 1 terminated NCT01705340
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery treatment 1 terminated NCT01100489
Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer No drug interventions treatment 2 withdrawn NCT00618657
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting treatment 2 completed NCT00228358
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine treatment 1 completed NCT00077376
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer treatment 2 completed NCT00039455
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer treatment 1 terminated NCT04273555
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging No drug interventions diagnostic 1 / 2 recruiting NCT03755141
Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer treatment 2 unknown_status NCT02362958
A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer treatment 2 completed NCT02963363
Adapted Physical Activity for Breast Cancer HER2 Positive Patient No drug interventions supportive_care Not Available terminated NCT03735966
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients. treatment 2 completed NCT02614794
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer treatment 2 completed NCT00817362
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer treatment 2 terminated NCT02213744
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients treatment 2 / 3 terminated NCT01983501
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer treatment 1 completed NCT01132664
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer treatment 1 / 2 terminated NCT05429684
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer treatment 3 unknown_status NCT04296942
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) treatment 1 terminated NCT05931042
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review Not Available Not Available completed NCT03632941
A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer treatment 2 active_not_recruiting NCT06537674
Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer Not Available Not Available not_yet_recruiting NCT05534438
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer No drug interventions treatment 2 recruiting NCT05253911
Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens. Not Available Not Available recruiting NCT06450314
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. No drug interventions treatment 2 not_yet_recruiting